Stage 4 pancreatic cancer requires a multifaceted approach combining systemic chemotherapy, biomarker-driven targeted therapy, and integrated palliative care to extend survival and maintain quality of life. Treatment decisions depend on performance status, tumor genetics, organ function, and patient goals, balancing aggressive regimens with gentler options tailored to individual circumstances. Key Takeaways FOLFIRINOX offers superior response rates for fit patients with ECOG